Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.
A 49-Year-Old Woman with BRCA Wild-Type Ovarian Cancer
An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.
A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.
Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.
An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.
Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.
Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.
Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.
Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
